IP Library Granted Patent US 10,092,588
Granted Patent B2
US 10,092,588 · App. 15/401,743 · Granted Oct 9, 2018

Foamable compositions, breakable foams and their uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,588
App. No.
15/401,743
Granted
Oct 9, 2018
Kind
B2
Abstract

A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.

Claims (64)

1. A foamable composition comprising:

an active agent consisting of one or more antibiotic agents;

at least about 60% by weight of a short chain alcohol;

a foaming booster, wherein the foaming booster is a polymeric agent;

between about 2% and about 50% of at least one organic carrier selected from the group consisting of a polar solvent, a hydrophobic organic carrier, and a mixture thereof;

an active herbal extract;

a metal; and

an antioxidant;

wherein the foamable composition is a surfactant free composition.

2. The foamable composition according to claim 1 , wherein the one or more antibiotic agents is a tetracycline antibiotic or a salt, ion, or complex thereof.

3. The foamable composition according to claim 1 , wherein the one or more antibiotic agents are about 0.1% to about 5% by weight of the composition.

4. The foamable composition according to claim 3 , wherein the one or more antibiotic agents are about 1% by weight of the composition.

5. The foamable composition according to claim 3 , wherein the one or more antibiotic agents are about 5% by weight of the composition.

6. The foamable composition according to claim 1 , wherein the antioxidant is about 0.1% to about 10% by weight of the composition.

7. The foamable composition according to claim 1 , wherein the short chain alcohol is ethanol.

8. The foamable composition according to claim 1 , wherein the at least one organic carrier is a polar solvent.

9. The foamable composition according to claim 8 , wherein the polar solvent is propylene glycol.

10. The foamable composition according to claim 1 , wherein the polymeric agent is a cellulose ether.

11. The foamable composition according to claim 10 , wherein the cellulose ether is a hydroxypropyl cellulose.

12. The foamable composition according to claim 8 , wherein the polar solvent is about 5% to about 25% by weight of the composition.

13. The foamable composition according to claim 12 , wherein the polar solvent is about 17% to about 23% by weight of the composition.

14. The composition according to claim 2 , wherein the one or more antibiotic agents are present in a therapeutically effective concentration.

15. The foamable composition according to claim 1 , wherein the polymeric agent is about 0.1% to about 5% by weight of the composition.

16. The foamable composition according to claim 1 , wherein:

the one or more antibiotic agents is a tetracycline antibiotic or a salt, ion, or complex thereof; the short chain alcohol comprises ethanol; the polymeric agent comprises a cellulose ether; and the at least one organic carrier comprises a polar solvent, wherein the polar solvent comprises a glycol.

17. The foamable composition according to claim 16 , wherein:

the tetracycline antibiotic is about 0.1% to about 5% by weight of the composition;

the cellulose ether is about 0.1% to about 5% by weight of the composition;

the glycol is about 5% to about 25% by weight of the composition; and

the antioxidant is about 0.1% to about 10% by weight of the composition.

18. The composition according to claim 17 , wherein the tetracycline antibiotic is about 1% by weight of the composition.

19. The foamable composition according to claim 17 , wherein the cellulose ether is hydroxypropyl cellulose.

20. The foamable composition according to claim 19 , wherein the glycol is propylene glycol.

21. The foamable composition according to claim 1 , further comprising a liquefied or compressed gas propellant.

22. The foamable composition according to claim 17 , wherein:

the cellulose ether is a hydroxypropyl cellulose; and

the polar solvent is a propylene glycol.

23. A foamable composition comprising:

an active agent consisting of an antibiotic;

at least about 60% by weight of a short chain alcohol;

a polymeric agent; and

between about 2% and about 50% of at least one organic carrier selected from the group consisting of a polar solvent, a hydrophobic organic carrier, and a mixture thereof;

wherein the foamable composition comprises no surfactant.

24. A non-surfactant carrier composition comprising:

an active agent consisting of an antibiotic;

at least about 60% by weight of ethanol;

a cellulose ether;

a glycol;

an active herbal extract;

a metal; and

an antioxidant,

wherein the non-surfactant carrier composition is surfactant free.

25. The non-surfactant carrier composition according to claim 24 , wherein the glycol comprises propylene glycol between about 2% and about 50% by weight of the composition.

26. The foamable composition according to claim 23 , wherein the at least one organic carrier is about 17% to about 23% by weight of the composition.

27. The non-surfactant carrier composition according to claim 25 , wherein the glycol comprises propylene glycol between about 17% and about 23% by weight of the composition.

28. The foamable composition according to claim 13 , wherein the polar solvent is about 17% by weight of the composition.

29. The foamable composition according to claim 13 , wherein the polar solvent is about 23% by weight of the composition.

30. The non-surfactant carrier composition according to claim 24 , wherein:

the antibiotic is a tetracycline antibiotic or a salt, ion, or complex thereof, and is about 0.1% to about 5% by weight of the composition;

the cellulose ether is hydroxypropyl cellulose and is about 0.1% to about 5% by weight of the composition; and

the glycol is propylene glycol and is about 17% to about 23% by weight of the composition.

31. The non-surfactant carrier composition according to claim 30 , wherein the antioxidant is about 0.1% to about 10% by weight of the composition.

32. The non-surfactant carrier composition according to claim 30 , wherein the ethanol is at least about 65% by weight of the composition.

33. The foamable composition according to claim 17 , wherein the glycol is about 17% to about 23% by weight of the composition.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0167 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
CHANGE OF NAME Recorded Aug 14, 2018
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 046780/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2017
From: TAMARKIN, DOV; ZIV, ENBAL; HAZOT, YOHAN; SCHUZ, DAVID
To: FOAMIX LTD.
Reel/Frame 042073/0265 →